Fermenta Biotech Ltd · BSE:FERMENTA
Fermenta Biotech — Investor Presentation (September 2023)
35 slides from Fermenta Biotech's investor presentation, Sep 15, 2023
Slide 1: BSE intimation letter for investor presentation
Ref: F.No.: 808 September 15, 2023 Corporate Relations BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Dear Sir, Sub.: Intimation of Investor Presentation – September 2023 Ref: Scrip Code: 506414 Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclo
Slide 2: Investor Presentation | September 2023
Investor Presentation | September 2023
Slide 3: Snapshot
Snapshot Top 3 Only manufacturer of Amongst top 3 manufacturers Global Presence in Vitamin D3 in India of Vitamin D3 globally 60+ countries Proprietary technology to 55 Years of Vitamin D3 Both manufacturing facilities certified manufacture Vitamin D3 manufacturing experience by global regulatory bo
Slide 4: Company Overview
Company Overview • Fermenta Biotech Limited (FBL) (Erstwhile DIL Ltd.) incorporated in 1951 by Dr. DVK Raju, is engaged in development and manufacturing of pharmaceuticals, biotechnology and Consolidated Revenue (INR Mn) & EBITDA Margins (%) environmental solutions used across various industries. 3,
Slide 5: Board Of Directors
Board Of Directors Mr. Sanjay Buch - Chairman, Independent Director Mr. Krishna Datla, Promoter & Executive Vice Chairman He holds a Bachelors Degree in Economics and Law and has over two A Commerce Graduate from Mumbai University having around 20 decades of experience in wide spectrum of legal work
Slide 6: Board Of Directors
Board Of Directors Mr. Vinayak Hajare, Non-Executive Independent Director Dr. Gopakumar Nair, Non-Executive Independent Director Qualified Masters degree holder in Financial management from He has a Ph.D from National Chemical Laboratory (NCL), Diploma in Jamnalal Bajaj Institute of Management Studi
Slide 7: Awards and Recognitions
Awards and Recognitions India Pharma Awards 2021 Excellence in Logistics Performance - Pharma Environment Leadership Award 2023 Excellence in R&D – India Logistics & Excellence in Promotion of Environment Development of new Warehousing Excellence product/technology (Runner up) Awards 2023 Conservati
Slide 8: FBL Features in the Media
FBL Features in the Media Press release coverage in CNBC TV 18 Press release coverage in Financial Express dated 8th September 2023 dated 15th June 2022 Coverage in Forbes India Issue dated 30th August 2019 ET Now interview telecast on its morning Press release coverage in Express Press release cove
Slide 9: Milestones
Milestones Leased land at Saykha for future expansion Enhanced Vitamin D3 --- Launch of Vitamin AD2 for Fermenta Biotech Ltd capacity at Dahej Merger of DIL and FBL was oil fortification established with its first Second plant for --- completed --- Establishment of enzyme manufacturing manufacturing
Slide 10: Geographical Presence
Geographical Presence Kullu Hamburg Delaware Nacogdoches Dahej, Saykha Thane Pennepalli, Geographical Revenue Mix % Andhra Pradesh (FY23) for Vit D3 and Other API R&D Centre and Registered Office ROW 28% India International Subsidiaries 36% Manufacturing Facility Delaware, USA: Fermenta Biotech USA
Slide 11: Manufacturing Plants
Manufacturing Plants Kullu (Himachal Pradesh) • Set up the Biotech plant in 1987 to manufacture Penicillin G Amidase and Acylase as well as CAL B enzymes. A new bulk drug division in 2004 to manufacture various APIs like Vitamin D3, Phenyramidol HCI and Silicon Powder. • In Q2 FY23 the plant for man
Slide 12: Accreditations & Certifications
Accreditations & Certifications* *Accreditations & Certifications are products / site specific Fermenta Biotech Limited 11
Slide 13: R&D and Quality
R&D and Quality R&D • Modern, fully equipped, DSIR approved Research & Development facility complemented by highly skilled and committed scientists. • Providing integrated solutions, processes and products for Biotech and Active Pharmaceutical Ingredients (API) • API R&D, combined with expertise on
Slide 14: Key Patents Granted in 2022
Key Patents Granted in 2022 1 Granted on November 14, 2022 • Improved Process for Extraction of Cholesterol from Fish Oil Waste Residue 2 Granted on July 12, 2022 • Mutant Penicillin G Acylases of Achromobacter CCM4824 (India) 3 Granted on June 15, 2022 • Chemo-Enzymatic Process For Synthesis Of Mol
Slide 15: Business Overview
BUSINESS OVERVIEW
Slide 16: About Vitamin D3
About Vitamin D3 For Humans • Vitamin D3 (Cholecalciferol) is a fat- • Vitamin D has been linked to a multitude of health benefits such as soluble vitamin, responsible for calcium general health and wellbeing, bone and mental health as well as absorption in the body. management and prevention of cer
Slide 17: FBL in Vitamin D3
FBL in Vitamin D3 CAGR Growth FY15 to FY23 Vitamin D3 Revenue (INR Mn) 18% • FBL is a leader in manufacturing Vitamin D3, and has 13% 27% 17% the distinction of being the only organization in India 34% 56% to manufacture Vitamin D3 69% 73% 83% • The company has a Non-China dependent supply 66% Volum
Slide 18: Manufacturing Process and Applications
Manufacturing Process and Applications Backward Integrated Manufacturing Process Vitamin D3 Applications Sheep Wool Scouring of Wool For Humans Cleaned Wool Wool Grease Pharmaceuticals Dietary and Nutritional Supplements Food and Beverage Fortification Lanolin Cholesterol For Animals 7-Dehydrocholes
Slide 19: Integrated Biotechnology Capabilities
Integrated Biotechnology Capabilities Heritage of innovation in enzymes One-stop Destination for Green Chemistry FBL’s core expertise spans from microbial screening, fermentation, immobilization, biocatalysis, enzyme-mediated antibiotic synthesis to API intermediates & APIs Expertise One-stop destin
Slide 20: Other Segments
Other Segments APIs & Other intermediaries Environmental Solutions • For over 25 years, FBL is • FBL’s Environmental Solutions provide unique a trusted and reliable source advantages in waste water treatment and of Phenyramidol HCl (muscle management through integrated relaxant) & Silicon Powder bio
Slide 21: Nutrition Portfolio
Nutrition Portfolio Nutritional Ingredients Fortified Rice Kernel • FBL sources Natural • FBL offers Fortified Rice Kernel (FRK) from its Astaxanthin for human and newly commissioned manufacturing facility in animal nutrition applications Andhra Pradesh. for the Indian subcontinent. Vitamins Customi
Slide 22: Nutraceutical Product Pipeline
Nutraceutical Product Pipeline Vitamin D3 and its various formats for Variants of Fat soluble vitamins Nutrition portfolio Pharmaceuticals Vitamin A Fortified Rice Kernel Dietary & Nutritional Supplements Food Vitamin E Natural Astaxanthin Feed Vitamin K1 Customized Premixes Veterinary Science Vitam
Slide 23: Growth Drivers
Growth Drivers Internal Factors • Strong manufacturing capabilities with enhanced capacity utilizations to meet YoY production targets • Enhancing control and reduced dependence by backward integration World- Class • Sales footprint in 60+ countries spread across the globe Innovation Facilities in •
Slide 24: Strategic Initiatives
Strategic Initiatives Enhanced Focus Exiting of non-core business activities and laying long term emphasis on expanding the Nutraceutical business. Capital Allocation Plans All future capital allocation will be focused towards Nutrition business. Real Estate Business The company has taken steps towa
Slide 25: Industry Overview
INDUSTRY OVERVIEW
Slide 26: Vitamin D3 Animal Feed Price Trend
Vitamin D3 500 Animal Feed Price Trend 85 80 75 60 Price (Euro/kg) 33 32 30 25 22 20 20 16 13 12 9 9 10 8 8 7 6 6 6 7 8 7 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 Q1 2023 Q2 2023 Calendar Year Source: feedinfo.com Min of Low Max of High Fermenta Biotech Limited 25
Slide 27: Vitamin D & Nutraceutical Industries & Drivers
Vitamin D & Nutraceutical Industries & Drivers VITAMIN D INDUSTRY • The Vitamin D market is estimated to account for about USD 1.25 billion in 2021 and is projected to reach a value of nearly USD 1.9 billion by 2027, growing at a CAGR of 7.1% from 2023 to 2027. • Vitamin D insufficiency affects almo
Slide 28: Financial Overview
FINANCIAL OVERVIEW
Slide 29: Historical Standalone Income Statement
Historical Standalone Income Statement PARTICULARS (INR Mn) Q1-FY24 FY23 FY22 FY21 Operational Revenue 768 3,289 3,880 3,728 Total Expenses 636 2902 3,120 2,791 Operational EBITDA 132 387 760 937 Operational EBITDA Margins (%) 17.19% 11.77% 19.59% 25.13% Other Income 21 76 75 66 Depreciation 57 245
Slide 30: Historical Standalone Balance Sheet
Historical Standalone Balance Sheet PARTICULARS (INR Mn) FY23 FY22 FY21 PARTICULARS (INR Mn) FY23 FY22 FY21 Equity 3,341 3,959 3,704 Assets Non-current Assets 4,114 3,974 3,745 a) Equity share capital 144 144 144 a) Property, plant and equipment 2,049 1,935 1,538 b) Other equity 3,197 3,815 3,560 b)
Slide 31: Historical Consolidated Income Statement
Historical Consolidated Income Statement PARTICULARS (INR Mn) Q1-FY24 FY23 FY22 FY21 Operational Revenue 824 3,499 3,985 3,773 Total Expenses 715 3,320 3,371 2,956 Operational EBITDA 109 179 614 817 Operational EBITDA Margins (%) 13.23% 5.12% 15.41% 21.65% Other Income 20 77 81 82 Depreciation 59 28
Slide 32: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet PARTICULARS (INR Mn) FY23 FY22 FY21 PARTICULARS (INR Mn) FY23 FY22 FY21 Equity 3,119 3,714 3,603 Assets a) Equity share capital 144 144 144 Non-current Assets 3,828 3,928 3,775 a) Property, plant and equipment 2,048 1,935 1,539 b) Other equity 3,002 3,577 3,462
Slide 33: Historical Consolidated Financial Performance
Historical Consolidated Financial Performance Operational Revenue (INR Mn) Operational EBITDA (INR Mn) & Margins (%) PAT (INR Mn) & Margins (%) 3,985 455 3,773 3,499 817 12.06% 154 2.18% 614 21.65% 3.86% 18 15.41% FY21 FY22 FY23 Q1-FY24 13.23% 824 179 5.12% 109 -14.72% -515 FY21 FY22 FY23 Q1-FY24 FY
Slide 34: Disclaimer
Disclaimer No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the d
Slide 35: Thank You
3 > x is is) <= ke
Fermenta Biotech — Investor Presentation (September 2023) on 6ix